FDA DEVICE FACTS
PrecivityAD2 Test
C2N Diagnostics, LLC
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The PrecivityAD2 test is an in vitro device that uses immunoprecipitation followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) to quantify β-Amyloid 1-42 (Aβ42) and β-Amyloid 1-40 (Aβ40) peptide concentrations, and phosphorylated and non-phosphorylated tau protein at amino acid threonine, position 217 (p-tau217 and np-tau217) peptide concentrations in human K2-EDTA plasma. An algorithm combines the Aβ42/40 ratio and the p-tau217/np-tau217 ratio x 100 (%p-tau217) to generate the Amyloid Probability Score 2 (APS2) result, a numeric value ranging from 0-100. The PrecivityAD2 test is indicated for use in adults aged 40 years and older who present with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer’s disease or other forms of cognitive decline. The PrecivityAD2 test is intended to be used in conjunction with clinical assessment to aid health care professionals experienced in the evaluation of cognitive impairment to identify patients with amyloid pathology associated with Alzheimer’s disease. The test is not intended as a screening or stand-alone diagnostic test.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。